Antiangiogenic Therapy in Gastroesophageal Cancer

Zhaohui Jin; Harry H Yoon

doi:10.1016/j.hoc.2017.01.008

Antiangiogenic Therapy in Gastroesophageal Cancer

Hematol Oncol Clin North Am. 2017 Jun;31(3):499-510. doi: 10.1016/j.hoc.2017.01.008. Epub 2017 Mar 22.

Authors

Zhaohui Jin¹, Harry H Yoon²

Affiliations

¹ Department of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
² Department of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: Yoon.harry@mayo.edu.

PMID: 28501090
DOI: 10.1016/j.hoc.2017.01.008

Abstract

Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti-human epidermal growth factor receptor 2 therapy.

Keywords: Angiogenesis; Checkpoint inhibitor; Esophageal cancer; Gastric cancer; Immunotherapy.

Publication types

Review

MeSH terms

Adenocarcinoma / blood supply
Adenocarcinoma / drug therapy*
Angiogenesis Inhibitors / therapeutic use*
Esophageal Neoplasms / blood supply
Esophageal Neoplasms / drug therapy*
Esophagogastric Junction / blood supply
Humans
Neovascularization, Pathologic / drug therapy*
Stomach Neoplasms / blood supply
Stomach Neoplasms / drug therapy*

Substances

Angiogenesis Inhibitors